SER
Serina Therapeutics, Inc.Company Information
- Company Name
- Serina Therapeutics, Inc.
- CIK
- CIK0001708599
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- SER: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SER
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-07-07
- Last sale
- 2026-03-23
- Shares purchased (TTM)
- 28,772
- Shares sold (TTM)
- 233,215
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,406,254
- Shares outstanding
- 16,385,000
- Ownership
- 8.58%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -4.21%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 23 | 25 | 3 | 9 | 6 | 4 | 4 | 3 | 6 | 9 | 8 | 0 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Accounts And Other Receivables Net Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Assets Current | 25 | 26 | 6 | 11 | 8 | 6 | 6 | 5 | 9 | 9 | 8 | 1 | ||||||
| Grants Receivable Current | - | - | - | - | - | - | - | 0 | 0 | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 2 | 3 | 0 | 0 | 1 | ||||||
| Restricted Cash Noncurrent | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | - | ||||||
| Finance Lease Right Of Use Asset | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Prepaid Expense Other Noncurrent | 0 | 0 | 0 | 0 | - | - | 0 | 0 | - | - | - | - | ||||||
| Assets | 26 | 27 | 7 | 12 | 9 | 7 | 7 | 7 | 11 | 11 | 9 | 12 | ||||||
| Accounts Payable And Accrued Liabilities Current | - | - | - | - | - | - | - | - | 2 | 4 | 2 | 2 | ||||||
| Accounts Payable Current And Noncurrent | - | - | - | - | - | - | - | 2 | - | - | - | - | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | ||||||
| Notes And Loans Receivable Gross Noncurrent | - | - | - | - | - | - | - | - | - | - | 11 | 10 | ||||||
| Accounts Payable Current | 2 | 3 | 2 | 3 | 2 | 1 | 1 | - | - | - | 1 | - | ||||||
| Accrued Liabilities Current | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | - | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 4 | 6 | 4 | 9 | 4 | 2 | 2 | 14 | 13 | 14 | 1 | 3 | ||||||
| Loans Payable Current | - | - | - | - | - | - | - | 10 | 10 | 10 | 4 | 2 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | 0 | 0 | - | - | ||||||
| Finance Lease Liability Current | - | - | - | - | - | - | - | - | 0 | 0 | - | - | ||||||
| Convertible Debt Current | - | - | - | 3 | - | - | - | - | - | - | - | - | ||||||
| Other Liabilities Current | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | - | 0 | 0 | - | - | 0 | - | ||||||
| Warrants And Rights Outstanding | - | - | - | - | 4 | 3 | 4 | - | - | - | 0 | - | ||||||
| Convertible Debt Noncurrent | 3 | 3 | 3 | - | - | - | 0 | 0 | - | - | 3 | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Liabilities | 7 | 10 | 7 | 11 | 7 | 5 | 6 | 21 | 27 | 15 | 5 | 4 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Long Term Loans Payable | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | ||||||
| Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | - | - | - | - | - | - | 0 | 0 | - | - | 36 | - | ||||||
| Preferred Stock Value | 0 | 5 | 5 | 5 | 5 | - | 0 | 0 | - | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 19 | 18 | -0 | 2 | 2 | 2 | 1 | -14 | -16 | -28 | -32 | -33 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 95 | 83 | 59 | 57 | 52 | 51 | 45 | 8 | 7 | 1 | 1 | 100 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | -0 | -0 | -0 | - | - | 0 | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -77 | -70 | -64 | -60 | -56 | -49 | -44 | -22 | -23 | -5 | -33 | -128 | ||||||
| Minority Interest | - | - | 0 | -0 | -0 | -0 | -0 | -0 | -0 | - | 0 | -0 | ||||||
| Liabilities And Stockholders Equity | 26 | 27 | 7 | 12 | 9 | 7 | 7 | 7 | 11 | 11 | 9 | 12 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | 0.01 | 0.01 | - | - | 0.01 | - | ||||||
| Preferred Stock No Par Value | - | - | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | 10 | 10 | - | 5 | 0 | - | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | 0 | 0 | - | - | 3 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | - | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 1 | 1 | 1 | 1 | - | 0 | 0 | 0 | 0 | - | - | ||||||
| Temporary Equity Liquidation Preference | - | - | - | - | - | - | 0 | 0 | - | - | 37 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 1 | 1 | 1 | 1 | - | 0 | 0 | 0 | 0 | - | - | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | 0 | 0 | - | - | 3 | 3 | ||||||
| Preferred Stock Liquidation Preference Value | 0 | 5 | 5 | 5 | 5 | - | 0 | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 200 | ||||||
| Common Stock Shares Issued | 25 | 15 | 11 | 11 | 10 | 10 | 9 | 9 | 9 | 8 | 2 | 38 | ||||||
| Shares Outstanding | 25 | 15 | 11 | 11 | 10 | 10 | 9 | 9 | 9 | 8 | 2 | 38 | ||||||
| Common Stock Dividends Shares | - | - | 0 | - | - | - | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSerina Therapeutics, Inc. (SER) — SEC Financial Statements & Analysis
Serina Therapeutics, Inc. (SER) is a pharmaceutical preparations company, incorporated in AL. Serina Therapeutics, Inc. trades on NYSE as: SER. Serina Therapeutics, Inc. (SER)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Serina Therapeutics, Inc. carries a market cap of $31.79M, a P/E ratio of -1.50x, a P/B ratio of 1.70x, a P/S ratio of 179.78x, an enterprise value of $11.85M, and an EV/EBITDA multiple of -0.45x. On profitability, it posts a gross margin of 6.30%, an operating margin of -19273.08%, a net margin of -16406.15%, a Return on Equity (ROE) of -208.44%, and a Return on Assets (ROA) of -122.20%. Per share, it reports EPS of $-1.30, diluted EPS of $-1.30, free cash flow per share of $-1.29, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 68.90% year-over-year, and EPS growth of 3.12% year-over-year. On the balance sheet, it maintains a current ratio of 6.65x, a quick ratio of 6.12x, working capital of $21.27M, a debt-to-equity ratio of 0.38x, a debt ratio of 0.27, an interest coverage ratio of -44.49x, free cash flow of $-21.20M (TTM), and net debt of $-19.94M. Figures sourced from SEC EDGAR.
- Market Cap
- $31.79M
- P/E TTM
- -1.50x
- EPS TTM
- $-1.30
- P/B TTM
- 1.70x
- ROE TTM
- -208.44%
- ROA TTM
- -122.20%
- Debt To Equity
- 0.38x
- Free Cash Flow TTM
- $-21.20M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Serina Therapeutics, Inc. in?
Serina Therapeutics, Inc. (SER) operates in the Pharmaceutical Preparations industry.
What exchange does SER trade on?
Serina Therapeutics, Inc. (SER) trades on the NYSE.
Where is Serina Therapeutics, Inc. incorporated?
Serina Therapeutics, Inc. is incorporated in AL.
When was Serina Therapeutics, Inc. (SER)'s most recent SEC filing?
Serina Therapeutics, Inc. (SER)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is SER's market cap?
Serina Therapeutics, Inc. (SER) has a market capitalization of $31.79M as of 2026-06-30.
What is SER's EPS (earnings per share)?
Serina Therapeutics, Inc. (SER)'s trailing twelve month EPS is $-1.30 as of 2026-06-30.
What is SER's ROE (return on equity)?
Serina Therapeutics, Inc. (SER)'s trailing twelve month Return on Equity (ROE) is -208.44% as of 2026-06-30.
What is SER's ROA (return on assets)?
Serina Therapeutics, Inc. (SER)'s trailing twelve month Return on Assets (ROA) is -122.20% as of 2026-06-30.
What is SER's EV/EBITDA?
Serina Therapeutics, Inc. (SER)'s trailing twelve month EV/EBITDA is -0.45x as of 2026-06-30.